ArticleBlood advances2026

Safe Accelerated Venetoclax Escalation: a phase 1b study of obinutuzumab plus venetoclax with daily ramp-up in CLL.

Jennifer L Crombie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.